Abstracts tagged "cardiovascular disease and systemic lupus erythematosus (SLE)"

Abstract Number: 623 • 2013 ACR/ARHP Annual Meeting
Lupus Patients Have a High Prevalence Of Abnormalities On Resting Electrocardiogram That Are Associated With Increased Risk For Cardiovascular Events
Zahi Touma¹, Paula Harvey², Dafna D. Gladman³, Arthy Sabapathy⁴ and Murray B. Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with lupus are at increased risk for cardiovascular disease (CVD). Abnormalities detected on resting electrocardiography (ECG) that may be associated with an increased…
Abstract Number: 2574 • 2012 ACR/ARHP Annual Meeting
Smoking, Autoantibodies and Vascular Events in Systemic Lupus Erythematosus
Johanna Gustafsson¹, Iva Gunnarsson¹, Susanne Pettersson¹, Agneta Zickert¹, Anna Vikerfors², Erik Hellbacher², Sonia Möller¹, Kerstin Elvin³, Henrik Källberg⁴, Julia F. Simard⁵ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Immunology and Transfusion Medicine,, Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Smoking is a risk factor for several autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Smoking is also a major risk…
Abstract Number: 2404 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus and/or Antiphospholipid Antibody Positive Patients: Two-Year Preliminary Analysis of Diet and Exercise Habits
Virginia Haiduc¹, Monica C. Richey¹, Sotiria Everett², Aeshita Dwivedi¹, Lisa Konstantellis¹, Hassan Ghomrawi³ and Doruk Erkan⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Healthcare Research and Policy, Weill Cornell Medical College, New York, NY, ⁴Rheumatology Dept, Hospital for Special Surgery, New York, NY
Background/Purpose: SLE patients have high rate of cardiovascular events due to increased prevalence of traditional cardiovascular disease (CVD)- and other lupus-related thrombosis risk factors. In…
Abstract Number: 2238 • 2012 ACR/ARHP Annual Meeting
Alpha-Chlorofatty Acid Does Not Correlate with Baseline Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
Mary A. Mahieu¹, Camelia Guild², Carolyn J. Albert³, George Kondos⁴, James Carr⁵, Daniel Edmundowicz⁶, David A. Ford⁷ and Rosalind Ramsey-Goldman⁸, ¹Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Pediatrics and Center for Outcomes Research, Saint Louis University, Saint Louis, MO, ³Saint Louis University, Saint Louis, MO, ⁴University of Illinois at Chicago, Chicago, IL, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Temple University School of Medicine, Philadelphia, PA, ⁷Department of Biochemistry and Molecular Biology, Saint Louis University, Saint Louis, MO, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Serum alpha-chlorofatty acid (α-ClFA) directly reflects in vivo myeloperoxidase activity, an important regulator of atherogenesis. The objective of our study was to investigate whether α-ClFA…
Abstract Number: 1708 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Cardiovascular Risk Equation
Michelle Petri¹ and Laurence S. Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis remains the major late cause of death in SLE. Yet, the "traditional" cardiovascular risk equations (Framingham, Reynolds, SCORE) consistently underestimate the risk. …
Abstract Number: 1711 • 2012 ACR/ARHP Annual Meeting
Association of Vascular Calcification and Perivascular Adipose Tissue of the Descending Aorta with Cardiovascular Events in SLE
Kelly J. Shields¹, Emma Barinas-Mitchell², Amy H. Kao³, Susan Manzi⁴ and Kim Sutton-Tyrrell², ¹Medicine, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Lupus Center of Excellence, Allegheny Singer Research Institute, Pittsburgh, PA, ⁴Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). We have shown that clinically CVD-free women with SLE have…
Abstract Number: 1434 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Morbidity in a Long-Term Follow-up Cohort of Systemic Lupus Erythematosus Patients in Southern Sweden
Ragnar Ingvarsson¹, Ola Nived², Gunnar Sturfelt³, Anders Bengtsson⁴ and Andreas Jönsen⁵, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ²Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁵Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: The main objective was to study the incidence of myocardial infarction in a cohort of patients with Systemic Lupus Erythematosus (SLE) assembled prospectively over…
Abstract Number: 634 • 2012 ACR/ARHP Annual Meeting
Adherence to Adult Treatment Panel III Guidelines for Systemic Lupus Patients
Matthew Basiaga and Lisabeth Scalzi, Rheumatology, Penn State Univ/ Hershey, Hershey, PA
Background/Purpose: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) has provided education and guidance for decades on the management of hypercholesterolemia.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].